ASN 2017

Showcasing the latest solutions for renal therapies

This past November in New Orleans, renal experts and organizations from around the world joined together to make ASN 2017 a successful event. At Baxter, we were proud to have the opportunity to show how our therapy options can advance the care healthcare professionals can provide for all their individual PD, HD, and acute patients.

BAXTER THERAPY SOLUTIONS

Optimizing treatments in all care settings

Peritoneal dialysis, hemodialysis and acute renal settings may have different needs, but the aim of these therapies is the same; to save and sustain patient lives in the best possible way. Our booth at ASN showcased how our HOMECHOICE CLARIA and AMIA advanced APD systems with the innovative SHARESOURCE Connectivity Platform have been designed to give patients more confidence in performing PD at home.

We also helped participants discover how the PRISMAFLEX System and CRRT solutions helps optimize patient outcomes in the demanding ICU environments.

And finally, we proudly showcased the possibilities of the new HDx therapy enabled by the THERANOVA dialyzer providing HDF performance and beyond as simple as HD.

Do not use THERANOVA dialyzers for HDF or HF due to higher permeability of larger molecular weight proteins such as albumin.

ASN NEWS & MEDIA

Proud to support 27 abstracts at ASN Kidney Week

Baxter supported a scientific exchange focused on new standards of renal care with the focus on how data, innovations and therapeutic practices can help provide the best possible outcomes for dialysis patients.

See it here

PRESS RELEASE

The role of the SHARESOURCE platform in helping the clinical management of PD patients

Baxter shared new data that identified a potential role for remote patient management in earlier identification of peritonitis and detection of catheter dysfunction based on more than 1 million PD treatments that the SHARESOURCE platform has managed globally.

FIND OUT MORE

PRESS RELEASE

New Clinical Data on HDx Enabled By THERANOVA

Review our press release on how studies have shown the removal of middle molecular weight uremic toxins with minimal albumin loss with standard hemodialysis equipment.

READ MORE HERE

PRESS RELEASE

Get the first book exploring the possibilities of expanded hemodialysis

This is your chance to deep-dive into the emerging evidence and fascinating hypotheses on HDx. This is highly recommended for all physicians, students and healthcare professionals who are interested in innovation and improved care solutions.

CLICK HERE

BOOK